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Effects of diabetes, insulin and antioxidants on NO synthase tially cytotoxic reactive oxygen species (ROS). ROS can
abundance and NO interaction with reactive oxygen species. attack, denature or modify structural and functional mol-
Background. Earlier studies have provided evidence for in- ecules and thereby cause cytotoxicity, tissue injury andcreased production of reactive oxygen species (ROS) and al-
dysfunction. Oxidative stress has been implicated in thetered nitric oxide (NO) metabolism in diabetes. This study was
pathogenesis of tissue injury and dysfunction in a wideintended to explore the effect of type I diabetes and its treatment
with insulin alone or insulin plus antioxidant-fortified diet on range of human diseases including atherosclerosis, infec-
expression of NOS isoforms and ROS interactions with lipids, tion, inflammation, neoplasm, degenerative disorders, met-
glucose and NO.
abolic diseases, radiation injury, ischemia-reperfusion andMethods. Rats with streptozotocin-induced diabetes were
hypertension, to mention but a few [1, 2].divided into once-daily insulin (ultralente)-treated, insulin plus
antioxidant (vitamin E and vitamin C)-treated and untreated Numerous studies have provided convincing evidence
groups. After four weeks, plasma malondialdehyde (MDA) and for the presence of oxidative stress and its role in the
tissue endothelial (eNOS), neuronal (nNOS) NO synthases, car- pathogenesis of the complications of diabetes [3–7]. ROS
boxymethyllysine (CML) and nitrotyrosine were determined.
react with and modify lipids, carbohydrates, proteins andResults. The untreated diabetic animals exhibited severe hy-
DNA resulting in cytotoxicity and dysfunction [8]. In addi-perglycemia, elevated blood pressure, increased plasma MDA,
high tissue CML and reduced tissue nitrotyrosine denoting en- tion ROS avidly react with nitric oxide (NO), which is a
hanced lipid, glucose and protein oxidation but reduced NO major signaling molecule with diverse biological functions
oxidation by ROS. This was coupled with significant reduction [9]. This can lead to functional NO deficiency and forma-of eNOS and nNOS expression in renal cortex and eNOS in the
tion of highly reactive nitrogen species such as peroxy-left ventricle. Insulin therapy partially lowered blood pressure,
nitrite [10] or peroxynitrous acid [11]. In turn, the lattertissue CML, plasma glucose and MDA, but significantly raised
eNOS expression and nitrotyrosine abundance to supranormal agents can attack, denature or modify various structural
levels. Combined insulin and antioxidant therapies resulted in and functional molecules [12, 13]. For instance, peroxyni-
normalization of blood pressure, plasma MDA, tissue CML and
trite can react with tyrosine or cysteine residues of the pro-nitrotyrosine without affecting glucose level or NOS expression.
teins producing nitrotyrosine or nitrocysteine, which areConclusion. Oxidative stress in untreated diabetes is associ-
ated with down-regulation of NOS isoforms and increased ROS- considered as footprint of ROS interaction with NO [3].
mediated oxidation of lipid and glucose, but not NO. Ameliora- Several in vivo and in vitro studies have demonstrated
tion of hyperglycemia with once-daily insulin administration marked down-regulation of NO production and NO syn-
alone results in up-regulation of NOS isoforms, reduction of
thase (NOS) abundance in diabetic animals as well aslipid and glucose oxidation and increased NO oxidation. How-
cultured endothelial and mesangial cells subjected toever, insulin plus antioxidant supplementation can normalize
all three parameters. simulated hyperglycemia [14–18]. In addition, oxidative
stress, which is a common feature of diabetes, potentially
can result in ROS-mediated NO inactivation, thus com-
Production of the high energy compounds that fuel pounding the effect of down-regulation of NOS. NO is
the biochemical, biophysical and mechanical functions the most potent endogenous vasodilator and as such plays
of the body is coupled with ongoing generation of poten- an important role in regulation of renal and systemic
vascular resistance, renal blood flow, glomerular filtration
rate (GFR) and tissue perfusion [19, 20]. UncontrolledKey words: diabetes, oxidative stress, nitric oxide, carboxymethylly-
sine, lipid peroxides, nitrotyrosine. hyperglycemia is invariably accompanied by increased
renal blood flow and GFR. Earlier studies using NOSReceived for publication July 3, 2002
inhibitors have suggested the role of NO in the genesisand in revised form August 9, 2002
Accepted for publication August 28, 2002 of elevated renal blood flow and GFR in uncontrolled
diabetes [21, 22]. 2003 by the International Society of Nephrology
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Uncontrolled diabetes is marked by hyperglycemia trogen, and stored at 70C. Plasma was separated and
stored at 70C until being processed.and elevation of circulating free fatty acids. ROS react
with glucose to produce highly reactive carbonyl com-
Measurement of plasma glucose andpounds that, in turn, can react with the free amino group
glycosylated hemoglobinof lysine residues leading to the formation of glycosy-
lated proteins [4, 7]. In addition, ROS avidly react with Blood glucose level was monitored with a portable
glucose-measuring device (Glucometer Elite, Bayer, Elk-the fatty acids to produce lipoperoxides that can, in turn,
attack various molecules, particularly proteins to gener- hart, IN, USA) using blood obtained by tail prick of con-
scious rat. Blood glycosylated hemoglobin was determinedate lipoxidation products [23, 24].
The present study was intended to explore the effects by the affinity column binding method, using the reagents
supplied by Sigma Chemical Co.of insulin therapy alone or insulin plus antioxidant ther-
apy on ROS-mediated oxidation of glucose, lipids and
Measurement of plasma malondialdehydeNO as well as NOS expression in rats with streptozo-
tocin-induced diabetes. The evidence reveals increased Plasma malondialdehyde (MDA) was measured by
high-pressure liquid chromatography as described in ourROS-mediated glucose and lipid oxidation, reduced
NOS expression and NO oxidation in untreated diabetes. earlier study [26].
Insulin therapy alone lessened lipid and glucose oxida-
Tissue preparationtion, but increased NO production and NO oxidation.
Antioxidant therapy augmented the effect of insulin ad- The frozen heart (left ventricle), aorta, and renal cor-
tex of the animals studied were homogenized (25% wt/ministration by limiting ROS-mediated oxidation of not
only lipids and glucose, but NO as well. vol) in a solution containing 10 mmol/L HEPES buffer,
pH 7.4, containing 320 mmol/L sucrose, 1 mmol/L ethyl-
enediaminetetraacetic acid (EDTA), 1 mmol/L dithio-
METHODS
threitol (DTT), 10g/mL leupeptin, and 2g/mL aproti-
Animals nin at 0 to 4C by means of a polytron homogenizer.
Homogenates were centrifuged at 12000  g for fiveNine-week-old male Sprague-Dawley rats weighing
300 to 350 g were randomly assigned to the normal con- minutes at 4C, and the supernatant was used for deter-
mination of tissue carboxymethyllysine (CML) content,trol rats fed regular diet (N  6), untreated diabetic rats
(N  6), diabetic rats treated with insulin alone (N  nitrotyrosine abundance and NOS expression. Protein
concentration was determined by means of a bicinchoni-5), and diabetic rats treated with the combination of in-
sulin and antioxidant-fortified diet (N  5). Animals as- nic protein assay kit (Pierce, Rockford, IL, USA).
signed to the diabetic group received streptozotocin
Measurement of tissue CML content(Sigma Chemical Co., St. Louis, MO, USA) 65 mg/kg
via tail vein. The control group received placebo injec- Noncompetitive enzyme-linked immunosorbent assay
(ELISA) was performed as described previously [27] withtion. The insulin-treated subgroups received ultralente
insulin (Eli Lilly Inc., Indianapolis, IN, USA) subcuta- slight modification. Briefly, each well of 96-well immuno-
plate was coated with 100L of the above tissue prepara-neously at an initial dosage of 3 units/100 g once daily.
The dosage was adjusted as needed using twice weekly tion diluted at final concentration of 0.8 to 3g protein/mL
in PBS containing 0.05% NaN3. The coated plate wasplasma glucose determinations. The antioxidant fortified
diet consisted of a rat chow containing -tocopherol 5000 kept at 4C overnight, followed by washing three times
with PBS containing 0.1% Tween 20 (buffer A). In pre-U/kg of food and ascorbic acid fortified deionized water
(1000 mg/L). The control diet consisted of regular rat liminary experiments we had found that the given protein
amounts were within the log-linear range of detection forchow containing -tocopherol 40 U/kg food and deion-
ized water. The diets employed in the study were pur- our ELISA technique. Each well was then blocked with
200 L of PBS containing 1% bovine serum albuminchased from Purina Mills Inc. (St. Louis, MO, USA).
Animals were observed for four weeks. Body weight was and 0.05% Tween 20 (blocking buffer) for 2 hours, then
washed three times with buffer A. After washing, 100 Ldetermined weekly. Tail arterial pressure was measured
by tail plethysmography as described in our earlier study of 1:2000 diluted mouse anti-CML monoclonal antibody
(ICN Biomedicals, Aurora, OH, USA) in blocking buffer[25]. Timed urine collections were obtained using meta-
bolic cages. At the conclusion of the four-week study were added to the wells. Plates were incubated for two
hours at room temperature and overnight at 4C. Wellsperiod, animals were anesthetized by intraperitoneal in-
jection of pentobarbital 50 mg/kg and killed by exsangui- were then washed three times with buffer A and incubated
with 100 L of 1:2000 horseradish peroxidase-conjugatednation using cardiac puncture. All of the tissues required
for further analyses were immediately excised, cleaned anti-mouse IgG antibody (Transduction Laboratories,
Lexington, KY, USA) in blocking buffer for two hours.with phosphate-buffered saline (PBS), frozen in liquid ni-
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Table 1. Body weight, plasma concentrations of glucose andAfter washing three times with buffer A, the wells were
glycosylated hemoglobin (HB-A1) and creatinine (PCr) andreacted with 100 L of tetramethyl benzidine (Pierce, creatinine clearance (CCr) in normal control rats fed regular
diet, untreated diabetic rats (DM), diabetic rats treated withRockford, IL, USA) for 20 minutes. The reaction was
once-daily ultralente insulin alone (DMI) or the combinationterminated by the addition of 100 L of 1.5 mol/L sulfuric
of insulin and vitamin E and C-fortified diet (DMIEC)
acid, and the absorbance at 450 nm was read on a micro-
Control DM DMI DMIECELISA plate reader (Soft Max; Molecular Device, Sun-
Body weight gnyvale, CA, USA). The results were expressed as optical
Week 0 30214 3267 3035 3135densities per g protein. Week 4 40434 29614b 3457 36410
Plasma glucosea
mg/dL 1065 52521c 1806b 16715bWestern blot analysis
HB-A1 % 6.590.76 11.950.44c 8.040.53 7.540.43
These measurements were carried out to determine PCr mg/dL 0.480.03 0.440.07 0.440.05 0.420.03
CCr mL/min/kg 6.900.58 10.150.86b 8.621.42 9.070.73the endothelial (eNOS) and neuronal (nNOS) NOS ex-
N 6 6 5 5pression and nitrotyrosine abundance, as previously de-
Data are mean  SEM.scribed [28, 29]. Anti-eNOS and anti-nNOS monoclonal a Average of plasma glucose levels measured twice weekly at 10:00
b P 	 0.05 versus control groupantibody and peroxidase-conjugated goat anti-mouse
c P 	 0.005 versus all other groupsIgG antibody were supplied by Transduction Laborator-
ies. Anti-nitrotyrosine antibody was purchased from Up-
RESULTSstate Biotechnology (Charlottesville, VA, USA). Briefly,
the tissue extracts (70 g of protein for aorta and heart General data
and 125g of protein for renal cortex) were size fraction- Data are summarized in Table 1. As expected, the un-
ated on 4 to 12% Tris-glycine gel (Novex, San Diego, treated diabetic subgroup exhibited marked hyperglyce-
CA, USA) at 120 V for two to three hours. After electro- mia and elevated glycosylated hemoglobin. Daily admin-
phoresis, proteins were transferred onto Hybond-ECL istration of ultralente insulin ameliorated hyperglycemia
enhanced chemiluminescence membrane (Amersham and lowered glycosylated hemoglobin concentration, but
did not reduce plasma glucose values to the level seen inLife Sciences, Arlington Heights, IL, USA) at 400 mA
the control animals. Concomitant use of antioxidant withfor 120 minutes, using the Novex transfer system. The
insulin did not significantly alter either plasma glucosemembrane was prehybridized in 10 mL of blocking buf-
level or glycosylated hemoglobin concentration in thefer containing 10% milk for one hour and then hybrid-
study animals. The mean daily insulin dosage in diabeticized for an additional 16 hour period at 4C in the same
animals treated with insulin alone (15.3  0.06 unit) wasbuffer containing 10 L of the given primary antibody
comparable with that used in the combined insulin and(1:1000). The membrane then was washed for 30 minutes
antioxidant-treated group (15.5  0.05 unit).in a shaking bath, with the wash buffer (Tris-buffered sa-
The untreated diabetic animals exhibited a significant
line containing 0.1% Tween 20) changed every five min- weight loss during the four-week study period. Insulin
utes prior to two hours of incubation in blocking buffer therapy prevented diabetes-induced weight loss and fa-
plus goat anti-mouse IgG-horseradish peroxidase at the cilitated the growth of animals, albeit at a moderately
final titer of 1:1000. The washes were repeated before slower rate than seen in the control animals. Antioxidant
the membrane was developed with a light emitting non- supplementation did not significantly affect body weight
radioactive method using ECL Western blotting detec- in the study animals. The untreated diabetic rats showed
tion reagents (Amersham Life Sciences). The membrane a significant rise in creatinine clearance, signifying glo-
merular hyperfiltration. Insulin therapy attenuated thewas then subjected to autoluminography from 30 seconds
diabetes-induced hyperfiltration but did not restore cre-to five minutes. The autoluminographs were scanned
atinine clearance values to the level seen in the controlwith a laser densitometer (model PD1211; Molecular
animals. Antioxidant supplementation did not signifi-Dynamics) to determine the relative optical densities of
cantly affect creatinine clearance in the study groups.the bands. In all instances, the membranes were stained
with Ponceau stain, which verified the uniformity of pro- Blood pressure data
tein load and transfer efficiency across the test samples.
In Figure 1, the untreated diabetic group exhibited a
steady rise in arterial pressure during the observation pe-Data analysis
riod. Once-daily administration of ultralente insulin sig-
Data are presented as mean  SEM. Analysis of vari- nificantly ameliorated the diabetes-induced elevation of
ance (ANOVA) with post hoc multiple comparison test blood pressure. Antioxidant supplementation augmented
and Wilcoxon signed-rank test were used in statistical the blood pressure lowering effect of insulin therapy lead-
analysis of the data. P values less than 0.05 were consid- ing to complete normalization of blood pressure in the
insulin-treated diabetic animals.ered significant.
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Fig. 1. Systolic blood pressure in the normal control rats fed regular
diet (; N  6), untreated diabetic rats (; DM; N  6), diabetic rats
treated with once-daily ultralente insulin alone (; DMI; N  5)
or the combination of insulin and vitamin E and C-fortified diet (;
DMIEC; N  5). *P 	 0.05 versus control and DMIEC groups;
†P 	 0.05 versus all other groups and week 0 values; ‡P 	 0.05 versus
DMIEC.
Fig. 3. Carboxymethyllysine (CML) content of kidney, aorta and heart
in the normal control rats fed regular diet (N  6), untreated diabetic
rats (DM, N 6), diabetic rats treated with once-daily ultralente insulin
alone (DMI, N  5) or the combination of insulin and vitamin E and
C-fortified diet (DMIEC, N  5). *P 	 0.05 versus control and
DMIEC groups.
Fig. 2. Plasma malondialdehyde (MDA) in the normal control rats fed
regular diet (N  6), untreated diabetic rats (DM, N  6), diabetic rats
treated with once-daily ultralente insulin alone (DMI, N  5) or the
combination of insulin and vitamin E and C-fortified diet (DMIEC, CML data
N  5). *P 	 0.005 versus other groups; †P 	 0.05 versus control and
Figure 3 shows that untreated diabetes resulted in aDMIEC groups.
significant rise in CML contents in all tested tissues. This
phenomenon is indicative of enhanced ROS mediated
protein carbonylation and formation of advanced glyca-Plasma MDA results
tion end product in diabetes [7]. Insulin therapy led to
Data are illustrated in Figure 2. The untreated diabetic a partial reduction of CML content in all tested tissues.
animals exhibited a marked increase in plasma MDA Concomitant administration of vitamins E and C with in-
concentration. This observation points to increased sulin therapy resulted in further reduction of tissue CML
ROS-mediated lipid peroxidation in the diabetic animals. content in all tested tissues to values, which were compar-
Insulin therapy resulted in a significant but incomplete able with those found in the control group.
reduction of plasma MDA concentration in diabetic ani-
Nitrotyrosine datamals. Concomitant administration of antioxidants, vita-
mins E and C with insulin resulted in complete normal- Untreated diabetic animals showed a significant reduc-
tion in nitrotyrosine abundance in the left ventricle andization of plasma MDA concentration.
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Fig. 4. Representative Western blots and corresponding group data
illustrating nitrotyrosine abundance of kidney cortex, aorta and heart
in the normal control rats fed regular diet (N  6), untreated diabetic
rats (DM, N 6), diabetic rats treated with once-daily ultralente insulin
alone (DMI, N  5) or the combination of insulin and vitamin E and
C-fortified diet (DMIEC, N  5). *P 	 0.005 versus control and
DMI groups; †P 	 0.05 versus other groups.
Fig. 5. Representative Western blots and corresponding group data
illustrating nitric oxide synthase (NOS) protein mass of kidney cortex,
aorta and heart in the normal control rats fed regular diet (N  6),
untreated diabetic rats (DM, N  6), diabetic rats treated with once-renal cortex compared with the control group (Fig. 4).
daily ultralente insulin alone (DMI, N  5) or the combination of
However, nitrotyrosine abundance in the aorta of the un- insulin and vitamin E and C-fortified diet (DMIEC, N  5). *P 	
0.05 versus other groups; †P 	 0.05 versus control and DM groups.treated diabetic animals was similar to that of the control
group. Insulin therapy alone increased nitrotyrosine abun-
dance in all tested tissues to values that were significantly
higher than those found in the control group. Concurrent
the aorta was unchanged in the untreated diabetic group.antioxidant therapy attenuated the insulin-induced rise
Insulin therapy alone raised the eNOS abundance in thein tissue nitrotyrosine abundance.
renal cortex, aorta and left ventricular tissues to values
NOS data that were significantly higher than those found in the
control group. In addition, insulin therapy alone restoredFigure 5 shows that the untreated diabetic animals
renal cortex nNOS to a near normal level. Concomitantexhibited a significant reduction in eNOS and nNOS
antioxidant supplementation had no additional impactabundance in the renal cortex and eNOS abundance in
the left ventricular tissues. However, eNOS abundance in on NOS abundance in the tested tissue.
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DISCUSSION centration [22, 31–33]. The reason for the variance in
the results of those latter studies with those of the presentThe untreated diabetic animals showed significant in-
study and previous studies from our group and othercreases in plasma MDA concentration and marked ele-
investigators is not clear. However, differences in thevation of tissue CML content. These findings point to
model used, duration of diabetes, severity of hyperglyce-ROS-mediated modifications of lipid, carbohydrate and
mia and other factors may be involved.protein molecules, denoting the presence of oxidative
Insulin therapy resulted in a significant increase in eNOSstress that is a known feature of diabetes [3, 5, 6].
and nNOS expression in the renal cortex and eNOSInterestingly, tissue nitrotyrosine abundance was sig-
expression in the aorta and left ventricle. This is consis-nificantly reduced in the untreated diabetic animals de-
tent with the known effect of insulin on NO productionspite presence of oxidative stress that could have raised
and eNOS expression in endothelial cells via activation ofnitrotyrosine abundance via ROS-NO interaction. This
phosphatidylinositol-3 kinase [34, 35]. Interestingly, eNOSphenomenon can be explained, in part, by the reduction
expression rose to supranormal values in all tested tissues.of NO production caused by down-regulation of eNOS
This phenomenon appears to be due to much greaterand nNOS coupled with elevation of glucose and free
amounts and higher peak levels of insulin experiencedfatty acids rendering them the dominant targets of ROS
with once-daily insulin administration than those experi-in the untreated diabetic rats. Accordingly, the byprod-
enced with physiological release of endogenous insulinucts of ROS interaction with glucose (CML) and fatty
[36]. Thus, given the up-regulatory action of insulin onacids (MDA) were increased, whereas that of ROS-NO
eNOS expression [14, 34, 35], the observed up-regulationinteraction (nitrotyrosine) was reduced in diabetic ani-
of eNOS to supranormal value in the insulin-treatedmals. If true, increased competition for ROS interaction
diabetic animals is not surprising.by glucose and fatty acids may have an NO-sparing effect.
Antioxidant therapy resulted in a significant reductionThis phenomenon together with attenuation of tubulo-
in arterial pressure in the insulin-treated diabetic ani-glomerular feedback response (occasioned by enhanced
mals. This phenomenon is consistent with the earlier
proximal tubular sodium reabsorption) [30] contributes
studies that demonstrated improvement in hypertension
to the associated rise in renal blood flow and glomerular by amelioration of oxidative stress in various forms of
filtration rate. genetic and acquired hypertension [26, 37–40].
Insulin therapy alone resulted in marked but incom- In the present study, diabetic rats were treated with
plete reductions of plasma glucose and MDA concentra- a once-daily injection of a long-acting insulin preparation
tions and tissue CML levels. The reduction in plasma resulting in a significant but incomplete reduction of
MDA and tissue CML was coupled with a significant plasma glucose concentration. Clearly, a more satisfac-
rise in tissue nitrotyrosine abundance. The latter could tory glycemia and, hence, oxidative stress control can be
be due to a constellation of increased NO production achieved by multiple daily injections of insulin, in which
capacity (up-regulation of NOS isoforms), residual oxi- case antioxidants’ supplementation may be of little added
dative stress associated with incomplete glycemia control benefit. However, complete normalization of blood glu-
and the reduction in competition by glucose and fatty cose concentration requiring multiple insulin injections
acids for interaction with ROS. is not always practical for long-term clinical management
Antioxidant therapy resulted in complete normaliza- of diabetic patients. Therefore, the use of dietary antioxi-
tion of MDA, CML and significant reduction in tissue dant supplementation can be an effective adjunct to once
nitrotyrosine levels in the insulin-treated animals. These daily insulin therapy in ameliorating the associated oxi-
findings can be explained by the interactions of vitamins dative stress. In fact, oxidative stress contributes to renal
E and C with ROS, which necessarily spared lipids, glu- injury and antioxidant supplementation mitigates renal
cose and NO alike from attack by ROS. disease in diabetic and non-diabetic rats [41].
The untreated diabetic animals exhibited a significant In conclusion, uncontrolled diabetes of four weeks du-
down-regulation of eNOS and nNOS protein expressions ration in rats is associated with enhanced lipid, glucose
in the renal cortex and of eNOS in the left ventricle. and protein oxidation, hypertension, down-regulation of
These findings are consistent with our earlier study dem- NOS expression and reduced nitrotyrosine abundance.
onstrating marked down-regulation of eNOS expression Once-daily insulin administration results in partial glyce-
in cultured endothelial cells subjected to simulated hy- mia control and incomplete correction of oxidative stress
perglycemia and insulin deprivation [14]. Other investi- and hypertension as well as up-regulation of eNOS ex-
gators have reported similar observations in numerous pression and nitrotyrosine formation. Concomitant anti-
in vivo and in vitro experiments [15–18]. In contrast, a oxidants therapy leads to complete correction of oxida-
number of other studies have shown up-regulation of NO tive stress, blood pressure and nitrotyrosine abundance.
production and NOS expression in diabetic animals and These findings support the potential benefit of antioxi-
dant therapy in diabetes.cultured endothelial cells exposed to high-glucose con-
Koo and Vaziri: Oxidative stress in diabetes 201
Reprint requests to N.D. Vaziri, M.D., MACP, Division of Nephrol- 20. Welch WJ, Wilcox CS, Thomson SC: Nitric oxide and tubulo-
glomerular feedback. Semin Nephrol 19:251–262, 1999ogy and Hypertension, UCI Medical Center, 101 The City Drive, Bldg
21. Komers R, Lindsley JN, Oyama TT, et al: Role of neuronal nitric53, Room 125, Route 81, Orange, California 92868, USA.
oxide synthase (NOS1) in the pathogenesis of renal hemodynamicE-mail: ndvaziri@uci.edu
changes in diabetes. Am J Physiol Renal Physiol 279:F573–F583, 2000
22. Sugimoto H, Shikata K, Matsuda M, et al: Increased expression
REFERENCES of endothelial cell nitric oxide synthase (ecNOS) in afferent and
glomerular endothelial cells is involved in glomerular hyperfiltra-
1. Rosenfeld ME: Inflammation, lipids, and free radicals: Lessons tion of diabetic nephropathy. Diabetologia 41:1426–1434, 1998
learned from the atherogenic process. Semin Reprod Endocrinol 23. Slatter DA, Bolton CH, Bailey AJ: The importance of lipid-
16:249–261, 1998 derived malondialdehyde in diabetes mellitus. Diabetologia 43:550–
2. Young IS, Woodside JV: Antioxidants in health and disease. J Clin 557, 2000
Pathol 54:176–186, 2001 24. Steinberg D, Lewis A: Conner Memorial Lecture. Oxidative modi-
3. Ceriello A, Mercuri F, Quagliaro L, et al: Detection of nitrotyro- fication of LDL and atherogenesis. Circulation 95:1062–1071, 1997
sine in the diabetic plasma: Evidence of oxidative stress. Diabeto- 25. Gonick HC, Ding Y, Bondy SC: Lead-induced hypertension: In-
logia 44:834–838, 2001 terplay of nitric oxide and reactive oxygen species. Hypertension
4. Horie K, Miyata T, Maeda K, et al: Immunohistochemical colocali- 30:1487–1492, 1997
zation of glycoxidation products and lipid peroxidation products 26. Vaziri ND, Ding Y, Ni Z, Gonick HC: Altered nitric oxide metabo-
in diabetic renal glomerular lesions. Implication for glycoxidative lism and increased oxygen free radical activity in lead-induced hyper-
stress in the pathogenesis of diabetic nephropathy. J Clin Invest 100: tension: Effect of lazaroid therapy. Kidney Int 52:1042–1046, 1997
2995–3004, 1997 27. Shibayama R, Araki N, Nagai R, Horiuchi S: Autoantibody
5. Nishikawa T, Edelstein D, Du XL, et al: Normalizing mitochon- against N-(Carboxymethyl) lysine: An advanced glycation end prod-
drial superoxide production blocks three pathways of hypergly- uct of the Maillard reaction. Diabetes 48:1842–1849, 1999
caemic damage. Nature 404:787–790, 2000 28. Vaziri ND, Ni Z, Wang XQ, et al: Downregulation of nitric oxide
6. Rosen P, Nawroth PP, King G, et al: The role of oxidative stress synthase in chronic renal insufficiency: Role of excess PTH. Am J
in the onset and progression of diabetes and its complications: A Physiol Renal Physiol 274:642–649, 1998
summary of a Congress Series sponsored by UNESCO-MCBN, 29. Vaziri ND, Liang K, Ding Y: Increased nitric oxide inactivation
the American Diabetes Association and the German Diabetes by reactive oxygen species in lead-induced hypertension. Kidney
Society. Diabetes Metab Res Rev 17: 189–212, 2001 Int 56:1492–1498, 1999
30. Thomson SC, Deng A, Bao D, et al: Ornithine decarboxylase,7. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-
kidney size, and the tubular hypothesis of glomerular hyperfiltra-products: A review. Diabetologia 44:129–146, 2001
tion in experimental diabetes. J Clin Invest 107:217–224, 20018. Betteridge DJ: What is oxidative stress? Metabolism 49(Suppl):
31. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF: High glu-3–8, 2000
cose increases nitric oxide synthase expression and superoxide anion9. Gryglewski RJ, Palmer RM, Moncada S: Superoxide anion is
generation in human aortic endothelial cells. Circulation 96:25–involved in the breakdown of endothelium-derived vascular re-
28, 1997laxing factor. Nature 320:454–456, 1986
32. Komers R, Allen TJ, Cooper ME: Role of endothelium-derived10. Squadrito GL, Pryor WA: The formation of peroxynitrite in vivo
nitric oxide in the pathogenesis of the renal hemodynamic changesfrom nitric oxide and superoxide. Chem Biol Interact 96:203–206, 1995
of experimental diabetes. Diabetes 43:1190–1197, 199411. van der Vliet A, Eiserich JP, O’Neill CA, et al: Tyrosine modifi-
33. Veelken R, Hilgers KF, Hartner A, et al: Nitric oxide synthasecation by reactive nitrogen species: A closer look. Arch Biochem
isoforms and glomerular hyperfiltration in early diabetic nephropa-Biophys 319:341–349, 1995
thy. J Am Soc Nephrol 11:71–79, 200012. Beckman JS, Beckman TW, Chen J, et al: Apparent hydroxyl
34. Kuboki K, Jiang Z, Takahara N, et al: Regulation of endothelialradical production by peroxynitrite: Implications for endothelial
constitutive nitric oxide synthase gene expression in endothelialinjury from nitric oxide and superoxide. Proc Natl Acad Sci USA
cells and in vivo: A specific vascular action of insulin. Circulation87:1620–1624, 1990
101:676–681, 200013. Graham A, Hogg N, Kalyanaraman B, et al: Peroxynitrite modi-
35. Zeng G, Quon M: Insulin-stimulated production of nitric oxidefication of low-density lipoprotein leads to recognition by the mac-
is inhibited by wortamannin. Direct measurement in vascular endo-rophage scavenger receptor. FEBS Lett 330:181–185, 1993
thelial cells. J Clin Invest 98:894–898, 199614. Ding Y, Vaziri ND, Coulson R, et al: Effect of simulated hypergly-
36. Galloway JA, Chance RE: Improving insulin therapy: Achieve-cemia, insulin, and glucagons on endothelial nitric oxide synthase
ment and challenges. Horm Metab Res 26:591–598, 1994expression. Am J Physiol Endocrinol Metab 279:E11–E17, 2000 37. Duffy SJ, Gokce N, Holbrook M, et al: Treatment of hypertension15. Keynan S, Hirshberg B, Levin-Iaina N, et al: Renal nitric oxide with ascorbic acid. Lancet 354:2048–2049, 1999production during the early phase of experimental diabetes melli- 38. Schnackenberg CG, Welch WJ, Wilcox CS: Normalization of
tus. Kidney Int 58:740–747, 2000 blood pressure and renal vascular resistance in SHR with a mem-
16. Trachtman H, Futterweit S, Crimmins DL: High glucose inhibits brane-permeable superoxide dismutase mimetic: Role of nitric ox-
nitric oxide production in cultured rat mesangial cells. J Am Soc ide. Hypertension 32:59–64, 1998
Nephrol 8:1276–1282, 1997 39. Vaziri ND, Oveisi F, Ding Y: Role of increased oxygen free rad-
17. Yagihashi N, Nishida N, Seo HG: Expression of nitric oxide ical activity in the pathogenesis of uremic hypertension. Kidney
synthase in macula densa in streptozotocin diabetic rats. Diabeto- Int 53:1748–1754, 1998
logia 39:793–799, 1996 40. Vaziri ND, Ni Z, Oveisi F, Tarnavsky-Hobbs DL: Effect of antiox-
18. Yu WJ, Juang SW, Chin WT: Insulin restores neuronal nitric idant therapy on blood pressure and nitric oxide synthase expres-
oxide synthase expression in streptozotocin-induced diabetic rats. sion in hypertensive rats. Hypertension 36:423–429, 2000
Life Sci 68:625–634, 2000 41. Reddi AS, Bollineni JS: Selenium-deficient diet induces renal
19. Gabbai FB, Blantz RC: Role of nitric oxide in renal hemodynam- oxidative stress and injury via TGF-beta1 in normal and diabetic
rats. Kidney Int 59:1342–1353, 2001ics. Semin Nephrol 19:242–250, 1999
